Loading
MEF2C (Myocyte-specific enhancer factor 2C) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.
Transcription activator which binds specifically to the MEF2 element present in the regulatory regions of many muscle-specific genes. Controls cardiac morphogenesis and myogenesis, and is also involved in vascular development. Enhances transcriptional activation mediated by SOX18.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant.
In plain words · MEF2C (Myocyte-specific enhancer factor 2C) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.
MEF2C (Myocyte-specific enhancer factor 2C) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.
Transcription activator which binds specifically to the MEF2 element present in the regulatory regions of many muscle-specific genes. Controls cardiac morphogenesis and myogenesis, and is also involved in vascular development.
No product in this corpus aims at MEF2C yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA MEF2C: RNA tissue enhanced (skeletal muscle 522 nTPM, tongue 231 nTPM); blood lineage group enriched (B-cells 189 nTPM, dendritic cells 100 nTPM, monocytes 83 nTPM); high antibody staining in 11 normal tissues; highest cancer staining melanoma (7 of 12 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Lymphoma); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas MEF2C tissue; Open Targets ENSG00000081189 associations
First described 1993. Earliest sequence paper UniProt cites for the protein: Leifer et al, Proc. Natl. Acad. Sci. U.S.A, 1993, "MEF2C, a MADS/MEF2-family transcription factor expressed in a laminar distribution in cerebral cortex". Source.
Sources: HGNC HGNC:6996 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q06413 (protein name, function text, keywords and locations (REST API)); CIViC gene MEF2C (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0))
Transcription activator which binds specifically to the MEF2 element present in the regulatory regions of many muscle-specific genes. Controls cardiac morphogenesis and myogenesis, and is also involved in vascular development. Enhances transcriptional activation mediated by SOX18. Plays an essential role in hippocampal-dependent learning and memory by suppressing the number of excitatory synapses and thus regulating basal and evoked synaptic transmission. Crucial for normal neuronal development, distribution, and electrical activity in the neocortex. Necessary for proper development of megakaryocytes and platelets and for bone marrow B-lymphopoiesis. Location: Nucleus; Cytoplasm, sarcoplasm (UniProt). Locus 5q14.3 (HGNC).
RNA: tissue enhanced (skeletal muscle 522 nTPM, tongue 231 nTPM), detected in all normal tissues. Blood: group enriched (B-cells 189 nTPM, dendritic cells 100 nTPM, monocytes 83 nTPM).
Medium: Adrenal gland, Caudate, Cerebellum, Fallopian tube, Gallbladder, Heart muscle, Hippocampus, Ovary.
Medium only: colorectal cancer, head and neck cancer, thyroid cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"MEF2C" OR ABSTRACT:"MEF2C" OR TITLE:"myocyte enhancer factor 2C" OR ABSTRACT:"myocyte enhancer factor 2C" OR TITLE:"Myocyte-specific enhancer factor 2C" OR ABSTRACT:"Myocyte-specific enhancer factor 2C") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MEF2C, not a curated reading list.